MSD has announced plans to start three late-stage studies of Keytruda in patients with metastatic castration-resistant prostate cancer. MSD has announced plans to start three late-stage studies of ...
French pharma will test investigational candidate alongside MSD’s Keytruda Sanofi has entered an agreement with MSD – known as Merck & Co in the US – to collaborate on a phase II trial evaluating its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback